Medtronic (NYSE:MDT) said today that the FDA approved its new SynchroMedII myPTM personal therapy manager intended for use in treating patients with chronic pain.
The newly cleared device works with the company’s SynchroMedII intrathecal drug delivery system and is designed to handle delivering on-demand boluses within therapeutic limits set by physicians, the Fridley, Minn.-based company said.
Read the whole story on our sister site, Drug Delivery Business News
The post Medtronic wins FDA nod for SynchroMedII myPTM drug therapy manager appeared first on MassDevice.
from MassDevice https://ift.tt/2D111nB
Cap comentari:
Publica un comentari a l'entrada